PharmaBiome and Roquette collaborate on development of tailored fibres

This partnership aims to design brand new nutrition and health ingredients targeting an optimal interaction with gut microbiota to contribute to a healthy diet.

Most countries are experiencing what is termed a “fibre gap”, where individuals lack at least 10g of fibre per day in their diet

PharmaBiome and Roquette have announced an agreement to use PharmaBiome’s technology, the NicheMap. This method allows the screening and the formulation of innovative prebiotic solutions using novel soluble fibres developed by Roquette.

Today, fibre intake is largely below recommendation in many countries, with a foreseeable increase in different health issues such as obesity, cardiovascular diseases, diabetes and intestinal diseases in the coming years. This deficit in fibre intake is currently called the “fibre gap” and means that most people are lacking at least 10g of fibre per day in their diet. Fibre is an important component of a healthy diet for the following reasons:

  • promotes digestive health,
  • has a prebiotic effect on the gut microbiota,
  • reduces the risk of chronic diseases,
  • controls blood sugar levels,
  • promotes satiety and weight management.

A partnership that targets an optimal interaction with gut microbiota

The use of different fibres by selective bacteria induces the production of molecules — metabolites — that will impact the host’s health. These fibres are qualified as prebiotics. To optimise the health benefits of a fibre, it is essential to understand how gut bacteria use their substrates and what the produced molecules are. Knowing the structural characteristics that make a prebiotic out of a fibre is key to produce new ingredients with specific health properties.

PharmaBiome is a biotech company with a deep understanding of the link between microbiome composition and function. They use their predictive microbiome technology NicheMapTM, and they have demonstrated strong capabilities to predict the effect of prebiotic fibres on both microbial composition and activity in the human gut.

Roquette aims at helping people to close the fibre gap with fibre ingredients easy to use for complementing consumers’ daily diets through fibre enrichment and supplement. Roquette has been working with PharmaBiome since Jul 2017. The group has previously used and approved the said technology on existing and prototyped fibre ingredients.

Dr Tomas de Wouters, CEO of PharmaBiome, stated: “This project is an important milestone in our long-term collaboration with Roquette taking the leap from understanding the effect of fibres to using our insights to develop and optimise fibre products. Our long-standing collaboration with Roquette is a great validation of the biological relevance of our NicheMapTM technology, expanding our understanding of the microbiome and its use in the field of prebiotics.”

Backed by more than 20 years of scientific evidence in the field of soluble fibres, Roquette has developed the NUTRIOSE soluble fibre range for several years. These ingredients contribute to selectively modulate the gut microbiota towards a healthier composition. Several studies have demonstrated the benefits of NUTRIOSE on blood sugar management, digestive health, satiety and sustained energy release. The overall results show that NUTRIOSE meets the requirements of the definition of a prebiotic as defined by ISAPP (International Scientific Association for Probiotics and Prebiotics). This partnership will be a key lever to extend the current fibre range.

Dr Laetitia Guérin-Deremaux, head of nutrition and health R&D at Roquette, said: “This project with PharmaBiome will allow Roquette to offer new microbiome-targeted fibres with scientifically proven health benefits. We are very pleased by the results of this continued collaboration which reinforces our commitment to delivering plant-based innovative ingredients to the food, nutrition and health sectors.”